SCORING SYSTEMS USED IN COMMUNITY-ACQUIRED PNEUMONIA: OPPORTUNITIES AND LIMITATIONS


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Severe pneumonia is associated with high mortality, so a timely and correct assessment of its severity plays an important role in the management of such patients. The article presents an analysis of modern recommendations for management of patients with severe community-acquired pneumonia, the advantages and disadvantages of scales for assessing the risk of an unfavorable outcome in patients with pneumonia.

Texto integral

Acesso é fechado

Sobre autores

O. Fesenko

Russian Medical Academy of Continuous Professional Education

Email: ofessenko@mail.ru
MD, Prof. at the Department of Pulmonology

A. Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Bibliografia

  1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151-210. doi: 10.1016/S0140-6736(17)32152-9.
  2. Prina E., Ranzani O.T., Torres A. Community-acquired pneumonia. Lancet 2015;386:1097-108. doi: 10.1016/S0140-6736(15)60733-4.
  3. Fine M.J., Smith D.N., Singer D.E. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am. J. Med. 1990;89:713-21.
  4. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997;336:243-50. Doi: 10.1056/ NEJM199701233360402.
  5. Woodhead M., Welch C.A., Harrison D.A., et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit. Care. 2006;10(Suppl. 2):S1. Doi: 10.1186/ cc4927.
  6. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82.
  7. Mandell L.A., Wunderink R.G., Anzueto A., et al. infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007;44(Suppl. 2):27 72. doi: 10.1086/511159
  8. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis. 2008;47:375-84
  9. Espana P.P., Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am. J. Respir. Crit .Care Med. 2006;174:1249 56. doi: 10.1164/rccm.200602-177OC
  10. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10. Doi: 10.1001/ jama.2016.0287.
  11. Marti C., Garin N., Grosgurin O., et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit. Care. 2012;16:R141.
  12. Chaimers J.D., Mandai P, Singanayagam A., et ai. Severity assessment toois to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409-20.
  13. Ranzani O.T., Prina E., Menendez R., et ai. New sepsis definition (Sepsis-3) and community-acquired pneumonia mortaiity. A validation and clinical decisionmaking study. Am. J. Respir. Crit. Care Med. 2017;196:1287-97. Doi: 10.1164/ rccm.201611-2262.
  14. Mortensen E.M., Coley C.M., Singer D.E., et ai. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team cohort study. Arch. Intern. Med. 2002;162:1059-64.
  15. Genne D., Sommer R., Kaiser L., et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2006; 25:159-66.
  16. Waterer G. Severity scores and community-acquired pneumonia. time to move forward. Am. J. Respir. Crit. Care Med. 2017;196:1236-38.
  17. Lim W.S., Baudouin S.V., George R.C., et al. BTS guidelines for the management of community acquired pneumonia in aduits: update 2009. Thorax. 2009;64(Suppi. 3):1-55.
  18. Antibiotic Expert Groups. Therapeutic guidelines: antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited. 2014.
  19. Cilloniz C., Ewig S., Polverino E., et al. Microbial aetiology of communityacquired pneumonia and its relation to severity. Thorax. 2011;66:340-46.
  20. Roson B., Carrataia J., Dorca J., et al. Etioiogy, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. 2001;33:158-65. doi: 10.1086/321808.
  21. Stralin K., Olcen P, Tornqvist E., Holmberg H. Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. Scand. J. Infect. Dis. 2010;42:426-34.
  22. Capelastegui A., Espana Eff., Bilbao A., et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC. Infect. Dis. 2012;12:134. doi: 10.1186/1471-2334-12-134.
  23. Singanayagam A., Chalmers J.D. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet. Respir. Med. 2013;1:653-62.
  24. Singanayagam A., Aliberti S., Cilloniz C., et al. Evaluation of severity scoreguided approaches to macrolide use in community-acquired pneumonia. Eur. Respir. J. 2017;50.
  25. Valley T.S., Sjoding M.W., Ryan A.M., et al. Association of intensive care unit admission with mortality among older patients with pneumonia. JAMA. 2015;314:1272-9.
  26. Renaud B., Santin A., Coma E., et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit. Care Med. 2009;37:2867-74. Doi: 10.1097/ CCM.0b013e3181b02dbb.
  27. Restrepo M.I., Mortensen E.M., Rello J., et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137:552-57.
  28. Molina J.A., Seow E., Heng B.H., et al. Outcomes of direct and indirect medical intensive care unit admissions from the emergency department of an acute care hospital: a retrospective cohort study. BMJ. Open. 2014;4:e005553.
  29. Jeon K., Yoo H., Jeong B.H., et al. Functional status and mortality prediction in community-acquired pneumonia. Respirology. 2017;22:1400-406. doi: 10.1111/resp.13072.
  30. Ahn B.K., tee Y.S., Kim Y.J., et al. Prediction model for mortality in cancer patients with pneumonia: comparison with CURB-65 and PSI. Clin. Respir. J. 2016 25 Sep.
  31. Sbiti-Rohr D., Kutz A., Christ-Crain M., et al. The National Early Warning Score (NEWS) for outcome prediction in emergency department patients with community-acquired pneumonia: results from a 6-year prospective cohort study BMJ. Open. 2016;6:e011021.
  32. Ranzani O, Taniguchi L., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr. Opin. Pu im. Med. 2018; 24:227-36.
  33. Menendez R., Martinez R., Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587-91. doi: 10.1136/thx.2008.105312.
  34. Frenzen F.S., Kutschan U., Meiswinkei N., et al. Admission lactate predicts poor prognosis independently of the CRB/CURB-65 scores in community-acquired pneumonia. Clin. Microbiol. Infect. 2018;24(3):306.e1-306.e6.
  35. Ranzani O.T., Monteiro M.B., Ferreira E.M., et ai. Reclassifying the spectrum of septic patients using iactate: severe sepsis, cryptic shock, vasoplegic shock and dysoxic shock. Rev. Bras. Ter. Intensiva. 2013;25:270-78. doi: 10.5935/0103- 507X.20130047.
  36. Bermejo-Martin J.F., Cilloniz C, Mendez R., et al. Lymphopénie community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMedicine. 2017;24:231-36. Doi: 10.1016/j. ebiom.2017.09.023.
  37. Marrie T.J., Lau C.Y., Wheeler S.L., et al. A controlled triai of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. community-acquired pneumonia intervention trial assessing levofioxacin. JAMA. 2000;283:749-55.
  38. Carrataia J., Fernandez-Sabe N., Ortega L., et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann. Intern. Med. 2005;142:165-72.
  39. Yealy D.M., Auble T.E., Stone R.A., et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann. Intern. Med. 2005;143:881-94.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies